No love for Ariad here on BV? Pretty nice start for Ponatinib, especially in light of the fact that it is a dirty drug, with a bad AE profile and a high discontinuation rate.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.